Tiziano Martini1, Rino Biguzzi1, Irene Francesconi1, Sabrina Lelli1, Maria Federica Currà1 and Beatrice Borsellino1,2.
1 Immunohematology and Transfusion Medicine Unit, AUSL Romagna, M. Bufalini Hospital, Cesena, Italy.
2 Department of Biomedicine and Prevention, PhD in
Immunology, Molecular Medicine and Applied Biotechnology, University of
Rome Tor Vergata, Rome, Italy.
Correspondence to: Dr.
Martini Tiziano, MD. Department of Immunohematology and Transfusion
Medicine Unit, AUSL Romagna, M. Bufalini Hospital, Cesena, Italy.
E-mail:
tiziano.martini@auslromagna.it; ORCID:0000-0003-3572-460X
Published: January 01, 2024
Received: November 10, 2023
Accepted: December 14, 2023
Mediterr J Hematol Infect Dis 2024, 16(1): e2024009 DOI
10.4084/MJHID.2024.009
This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0),
which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
|
To the editor
The
P system was traditionally constituted by the antigens P1, P, and PK.
The recent International Society of Blood Transfusion (ISBT)
classification identifies two different systems, P1PK and GLOB. The two
most common phenotypes are P1 (present in 79% of Caucasians and 94% of
African Americans, characterized by P1 and P antigens on red blood cell
surface) and P2 (present in 21% of Caucasians and 6% of African
Americans, with only the P antigen presence). The anti-P1 antibody is
present in about two-thirds of P2 individuals, and it is often natural;
it is frequently an IgM reactive at temperatures <25°C, rarely
clinically relevant, and able to activate the complement.[1] Nevertheless, rare acute and delayed haemolytic transfusion reactions (HTR) have been reported (Table 1).[2-8]
|
- Table 1. Case reports of hemolytic transfusion reactions and literature review.
|
An
84-year-old man was admitted to the hospital for melaena, causing
severe anaemia, and requested a transfusion of 2 packed red blood cells
(PRBC) units. He was previously transfused with 2 units of PRBC in 2003
for unknown reasons. We initially performed a complete blood test and
indirect Antiglobulin test (IAT) through the microcolumn method, using
the Ortho Vision instrument (Ortho Clinical Diagnostics, Raritan, New
Jersey, U.S.). The IAT resulted in being negative, and the direct group
determination resulted in being 0 positive, whereas, in the indirect
group determination, we observed an unexpected reaction with 0 cells
(score 1+). This led us to speculate about an interference given by a
cold antibody, not visible at a 37°C incubation. Therefore, we repeated
the IAT at room temperature (RT) using the instrument and the test
tube; both resulted in positive. The Direct Antiglobulin test (DAT) and
self-control test were negative. To try and identify the suspected cold
antibody, we performed a C untreated (UNT) panel by hand incubating the
patient's plasma, using the Neutral cards and panel cells at 4°C, which resulted being positive in 3 cells out of 11, preventing us from identifying any antibodies.
Given that the blood request was urgent, crossmatch tests were carried
out on 3 fresh PRBC units: two of them proved to be compatible, so they
were delivered for transfusion. The patient was transfused with both
the PRBCs on the same day without any adverse reactions. The day after,
we performed the B panel using Reverse
cards, polyethylene glycol (PEG)-rich gel microcolumn, at 4°C and we
obtained more evident reactions that allowed us to start suspecting the
presence of an anti-P1 alloantibody. We also repeated the C UNT panel,
and we performed a 4°C IAT using the Reverse
cards. These tests confirmed our hypothesis about the presence of an
anti-P1 alloantibody because the positive and negative reactions
obtained matched those expected in the P1 antibody master list.
Eventually, the patient was tested for the P1 antigen, and it was
negative, as expected.
The anti-P1 antibody, often present in P2 individuals, is rarely reported as a cause of severe acute or delayed HTRs (Table 1).[2-8]
Recently, Smith et al.[2] reported a clinically mild
acute HTR (AHTR) in a young man caused by an IgM anti-P1 antibody
reactive at 37°C. The patient was transfused with 2 PRBC units,
assigned through the capture-R solid phase (which does not detect IgM
autoantibodies), and developed an AHTR. Routine antibody screening
methods can lead to missing clinically significant IgM antibodies
because they are designed to detect IgG antibodies.
Arndt et al.[3] reported an AHTR in a woman caused by
an anti-P1 that reacted at 37°C. In this case, the antibody was not
found before transfusion when a prewarmed crossmatch was done on 2 PRBC
units. In fact, a low-ionic-strength saline (LISS) additive was not
used, and a polyspecific antiglobulin serum was not added.
Thakral et al.[4] reported a case of a pregnant woman
who developed an AHTR straight after the start of the transfusion of a
PRBC unit. The Anti-P1 antibody was missed on immediate spin crossmatch
and was then detected on extended incubation for half an hour.
The most recent delayed HTR (DHTR) was reported in 2016 by Bezirgiannidou et al.,[5]
describing a case of a pregnant woman suffering from thalassemia
intermedia in need of a transfusion of PRBC units. The patient was
typed P1 negative, while her husband was P1 positive. She received a
phenotypically matched transfusion (but not matched for P1 antigen). On
day 19, during pre-transfusion tests, DAT resulted positive against
anti-C3d, and IAT resulted positive against P1+ erythrocytes at 37°C,
22°C and 4°C showing the presence of an anti-P1 alloantibody (gel
microcolumn tests). On day 29, she developed a DHTR. The extensive
screening revealed the presence of an IgM autoantibody with anti-I
specificity, demonstrating that the patient suffered from autoimmune
hemolysis, manifesting as a DHTR followed by a cold agglutinin
syndrome. Therefore, in thalassemic pregnant women, it would be useful
to avoid PRBC units with antigens absent on maternal erythrocytes and
present on paternal ones.
Two others severe DHTRs due to anti-P1 have been reported. The first
was described in 1981 regarding a woman who developed a DHTR 48 hours
after several PRBC unit transfusions, with evidence of an anti-P1 IgM
with a wide thermal range. In this case, the PRBC units were delivered
with no cross-matching,[6] and the second, reported by Girelli et al.,[7]
regarded a child who underwent surgery. In this case, the anti-P1
antibody was detected at admission, reacting only at 22°C, and 4 PRBC
units were crossmatched and resulted in compatibility. However, after 5
days, the patient needed a PRBC unit, and one of the units crossmatched
five days before was transfused. Forty-eight hours after transfusion,
she developed a DHTR, and an anti-P1 antibody, detected at room
temperature and 37°C, was demonstrated. In this case, probably
crossmatching the last unit before the second operation could have
demonstrated incompatibility at 37°C.
A case of successful anti-P1 identification was reported by Thulasiram and colleagues[8]
in a patient suffering from a pancreas periampullary carcinoma.
Similarly to our case, they started investigating the presence of a
cold alloantibody due to a reaction in the O cells of the indirect
grouping. Therefore, they performed 3-cell and 11-cell panels
(microcolumn) at different temperatures (4°C, 24°C, 37°C), having a
strong reaction at 4 °C which would fade gradually while raising the
temperature, confirming the presence of an IgM antibody. The patient
proved to be phenotypically negative for the presence of P1 antigen, so
they crossmatched P1 negative PRBC units, which were eventually
transfused without any transfusion reactions.
In conclusion, we presented a case report in which we successfully
prevented a possible HTR due to the antibody screening and the
crossmatch, which allowed us to suspect the presence of a cold antibody
interfering with the indirect group determination. From this
observation, we performed an antibody screening and, subsequently, the
identification panels at LT and 4°C. Moreover, the use of Reverse cards, which are richer in PEG gel compared to the Neutral cards (3% versus 1% respectively), permitted us to detect the cold alloantibody due to the enhancement of the reaction.
Based on our experience and analysis of methods used by several authors,[2-8]
we would suggest suspecting the presence of a cold antibody, which in
some cases could be clinically significant, every time there is an
unexpected reaction in the control column of the indirect group and
crossmatching PRBC units for such patients. We would additionally
recommend that tests performed to identify the cold antibody be carried
out also at LT and 4°C, preferring the use of Reverse cards; these are richer in PEG gel compared to the Neutral
cards and, therefore, more sensitive in detecting the alloantibody.
Furthermore, in the case of patients who require PRBC units to be
matched phenotypically, such as individuals affected by
hemoglobinopathies, we suggest studying P antigens and selecting
P1-compatible PRBC units. Finally, in the case of pregnant patients, it
would be convenient to avoid PRBC units with antigens absent on
maternal erythrocytes and which are present on paternal ones.
Authors’ contributions
TM,
BB, RB, and IF designed the study, interpreted the data, and wrote the
manuscript. SL and MFC helped in data interpretation. All authors
reviewed and approved the final version of this manuscript.
References
- Gassner C, Castilho L, Chen Q, et al. International
Society of Blood Transfusion Working Party on Red Cell Immunogenetics
and Blood Group Terminology Report of Basel and three virtual business
meetings: Update on blood group systems.
- Smith D, Aye T, Er LS, et al. Acute Hemolytic
Transfusion Reaction due to Anti-P1: A Case Report and Review of
Institutional Experience. Transfus Med Hemother. 2019;46(5):380-383. https://doi.org/10.1159/000490897 PMid:31832064 PMCid:PMC6876609
- Arndt PA, Garratty G, Marfoe RA, et al. An acute
hemolytic transfusion reaction caused by an anti-P1 that reacted at 37
degrees C. Transfusion. 1998;38(4):373-7. https://doi.org/10.1046/j.1537-2995.1998.38498257376.x PMid:9595020
- Thakral B, Bhattacharya P, Agnihotri N, et al.
Acute hemolytic transfusion reaction by anti-P1 antibody in pregnancy.
Am J Hematol. 2005;78(2):163-4. https://doi.org/10.1002/ajh.20264 PMid:15682413
- Bezirgiannidou Z, Christoforidou A, Kontekaki E, et
al. Hyperhemolytic Syndrome Complicating a Delayed Hemolytic
Transfusion Reaction due to anti-P1 Alloimmunization, in a Pregnant
Woman with HbO-Arab/β-Thalassemia. Mediterr J Hematol Infect Dis.
2016;8(1):e2016053. https://doi.org/10.4084/mjhid.2016.053 PMid:27872733 PMCid:PMC5111518
- Chandeysson PL, Flye MW, Simpkins SM, et al.
Delayed hemolytic transfusion reaction caused by anti-P1 antibody.
Transfusion. 1981;21(1):77-82. https://doi.org/10.1046/j.1537-2995.1981.21181127489.x PMid:7466910
- Girelli G, Pupella S, Perrone MP, et al. Transfusion reaction caused by anti-P1 antibody. Transfus Sci. 1993;14:405-407. https://doi.org/10.1016/S0955-3886(05)80014-1
- Thulasiram N, Sahoo D, Basavarajegowda A. Clinical
significant anti-P1 antibody with wide thermal amplitude: A tale of
successful blood management. Asian J Transfus Sci. 2023;17(1):125-127. https://doi.org/10.4103/ajts.ajts_165_21 PMid:37188025 PMCid:PMC10180787